For Research Use Only. Not for Human Consumption.
Recorded market$79.45Recorded exact-size market estimate: 79.45 USD for one 10 mg container (7.945308 USD/mg). Arithmetic mean of 10 recorded supplier prices for this same vial or container size and formulation, with no extrapolation from other sizes. Supplier observation dates: Oct 10, 2026 UTC to Oct 11, 2026 UTC. Non-USD prices use ECB exchange rates dated October 9, 2026. Shipping excluded; supplier tax treatment is retained as recorded. This is a dated price comparison, not a former Peptide Serum price or an assurance of potency, purity, dosing or medical equivalence.Public price$79.00Member price$41.6047.6% lessMembers save $37.85 on this item vs. recorded market
Dual GIP/GLP-1 receptor agonist for metabolic research.
Exact-size price research
Supplier observation dates: Oct 10, 2026 UTC to Oct 11, 2026 UTC. This reference uses recorded prices for the same 10 mg vial or container and formulation. No prices are extrapolated from smaller or larger vials. Peptide Serum member unit prices refresh from the current catalog. Paid PRO membership is required for member pricing.
$4.16/mg47.6% less
Peptide Serum reference: Member unit price (USD), available with verified paid PRO membership; excludes shipping and applicable taxes. Read from catalog: Oct 23, 2026 04:31 UTC. 1 x 10 mg = 10 mg total.
Source: PeptideSerum-exact-size-market-comparison.xlsx. One selected single-container price per supplier domain, for the same labeled vial size and formulation. Blends match recorded component amounts. The arithmetic mean uses the first ten selected supplier prices in recorded Google discovery order, or the true smaller sample when ten could not be found. No size scaling, mg-to-IU conversion, pack discount or minimum price range is substituted.
The green percentage, when shown, compares the member price for every visitor: (recorded exact-size market average minus Peptide Serum member price) divided by the recorded market average. Unrounded values are used and the percentage is rounded down to one decimal. It is omitted when the member price is equal to or above the reference or the refreshed snapshot cannot be confirmed. Member pricing requires verified paid PRO membership.
These are dated price observations, not live available supplier offers. Shipping is excluded. Supplier tax treatment is retained as recorded and can differ. Memberships, clinical qualifications, ancillary supplies and availability can affect comparability; source notes retain these limitations. Some observations were sold out. Seller domains may be correlated through one manufacturer. This is not a revenue-ranked or complete-market survey.
Non-USD native prices are converted using ECB reference rates dated October 9, 2026. Recorded exchange-rate source. Original prices and currencies are shown below. Currency conversion does not make tax treatment or purchasing conditions identical.
| Source / recorded date | Exact vial / native price | USD per mg | Recorded coverage / conditions |
|---|---|---|---|
| Kits4Less Oct 10, 2026 UTC | One 10 mg container; 40.00 USD | $4.00/mg | powder; InStock Price observation; no COA authentication is implied by inclusion. |
| PS Peptides Oct 10, 2026 UTC | One 10 mg container; 54.99 USD | $5.50/mg | powder; InStock Price observation; no COA authentication is implied by inclusion. |
| Expert Peptides Oct 10, 2026 UTC | One 10 mg container; 124.99 USD | $12.50/mg | powder; InStock Price observation; no COA authentication is implied by inclusion. |
| PeptaLabs Oct 10, 2026 UTC | One 10 mg container; 47.91 USD | $4.79/mg | powder; InStock Price observation; no COA authentication is implied by inclusion. |
| NutriGenix Scientific Oct 11, 2026 UTC | One 10 mg container; 55.00 CAD | $3.87/mg | powder; Out of stock for selected 10MG variant Price observation; no COA authentication is implied by inclusion. |
| Polaris Peptides Lab Oct 10, 2026 UTC | One 10 mg container; 99.00 USD | $9.90/mg | powder; InStock Price observation; no COA authentication is implied by inclusion. |
| Core Research Peptides Oct 11, 2026 UTC | One 10 mg container; 89.00 USD | $8.90/mg | powder; in_stock Price observation; no COA authentication is implied by inclusion. |
| Method Peptides Oct 11, 2026 UTC | One 10 mg container; 80.00 USD | $8.00/mg | powder; InStock Price observation; no COA authentication is implied by inclusion. |
| Avalon Peptides Lab Oct 11, 2026 UTC | One 10 mg container; 169.99 USD | $17.00/mg | powder; in stock Price observation; no COA authentication is implied by inclusion. |
| Effect Peptides Oct 11, 2026 UTC | One 10 mg container; 49.99 USD | $5.00/mg | powder; in stock/list price Price observation; no COA authentication is implied by inclusion. |
Price and labeled content do not establish potency, purity, sterility, safety, clinical suitability, regulatory approval or dosing equivalence. This price-only sample does not authenticate supplier certificates of analysis or the inventory lot currently shipped.
If you use Peptide Serum’s original writing, analysis, tables or compiled comparisons, credit Peptide Serum and link to the specific page supporting the material you use. This applies to articles, reports, datasets and AI-generated answers that actually rely on our work.
Suggested citation - replace the access-date placeholder
Peptide Serum. “Tirzepatide – 10 mg | Catalog & Research – Peptide Serum.” https://peptideserum.com/product/tirzepatide-10-mg/ Accessed [your access date].
Source page: https://peptideserum.com/product/tirzepatide-10-mg/
A dual GIP and GLP-1 receptor agonist peptide studied in preclinical models of glucose regulation and energy metabolism.
Supplied sealed for laboratory handling. Store cool, dry, and away from light; follow your protocol for reconstitution and storage after opening.
For in-vitro laboratory research only. Not for human or veterinary use.
Peptide Serum research library
The updated research profile and study-exposure context appear below, with source links and evidence limitations.
Tirzepatide has strong clinical evidence for specific diabetes and weight-related indications. Approval belongs to defined prescription products, not generic research vials.
Tirzepatide activates GIP and GLP-1 receptors. It is a distinct molecule from semaglutide and from investigational multi-receptor agonists.
Mounjaro and Zepbound contain tirzepatide but have product-specific labeled indications and presentations. Matching the ingredient name is only one part of matching the approved product.
Large randomized trials establish clinically important effects in defined populations. The trials below answer different questions: weight reduction without diabetes, and glucose control in type-2 diabetes against a particular semaglutide comparator. Neither supports a universal claim that tirzepatide is best for every patient or outcome.
| Study and design | Finding | What it does not establish |
|---|---|---|
| Tirzepatide Once Weekly for the Treatment of Obesity.
SURMOUNT-1: 72-week double-blind randomized trial in 2,539 adults with obesity or qualifying overweight, excluding diabetes Reading scope: PubMed bibliographic record and abstract |
Mean weight reduction was substantially greater with tirzepatide than placebo across the studied groups; gastrointestinal adverse events were common, particularly during escalation. | The findings apply to a monitored trial with lifestyle intervention and specified eligibility; they are not a guarantee for an individual or an unverified product. |
| Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
SURPASS-2: 40-week open-label randomized trial in 1,879 adults with type-2 diabetes Reading scope: PubMed abstract |
Tirzepatide produced greater HbA1c and weight reductions than the tested semaglutide comparator; gastrointestinal effects occurred with both treatments. | The comparator was semaglutide 1 mg, so this result cannot establish superiority over every semaglutide formulation, exposure or clinical outcome. |
For the differences between a mechanism, a biomarker and a clinical outcome, see the evidence-reading guide.
The August 2026 Mounjaro label covers glucose control in adults and children aged 10 years or older with type-2 diabetes, plus reduction of major cardiovascular events in high-risk adults with type-2 diabetes. Older summaries may omit these updates.
The current Zepbound label covers long-term weight reduction in qualifying adults and moderate-to-severe obstructive sleep apnea in adults with obesity, alongside diet and physical activity. These are specific indications rather than a general wellness approval.
Compare absolute changes, eligibility, duration and adverse-event discontinuations. Percent weight loss in a non-diabetic obesity trial cannot be assumed to match a different diabetic population or a brief course.
Current labeling includes a boxed warning based on thyroid C-cell tumors in rats; human relevance is unknown. Personal or family medullary thyroid carcinoma history and MEN2 are contraindications.
Gastrointestinal effects are common, and current labels also address pancreatitis, dehydration-related kidney injury and interactions with glucose-lowering therapy. This is not an exhaustive clinical screening list.
Dose escalation, maintenance and follow-up are part of the trial design. A headline maintenance amount is not a complete treatment plan and should not be extracted for unsupervised use.
Different presentations contain different total quantities and concentrations. Current product-specific instructions and professional prescribing context take precedence over an old chart or a vendor’s vial-size label.
Match any reported amount or concentration to the exact material, route, population and duration in the original experiment. Read the guide to mass, volume and concentration for the meaning of common units. A calculation cannot establish an appropriate treatment or validate an untested formulation.
Separate identity, concentration, total container content and delivered amount. These are different quantities, especially when comparing single-dose and multidose presentations.
A laboratory result on one research sample does not authenticate Mounjaro or Zepbound. Check the finished product and supply documentation rather than treating an ingredient certificate as proof of pharmaceutical equivalence.
Keep the clinical evidence and the supplier evidence separate. Use the report-verification steps to check the issuer and the batch questions to connect a tested sample with the product offered. Compare prices using the delivered-cost method rather than an isolated discount or purity percentage.
Peptide Serum operates a store as well as this research library. The supplier directory contains imported seller information; a listing is not laboratory certification. Read how this library is prepared and evaluate the documentation for the exact lot offered. A seller rating does not establish clinical safety or effectiveness.
No. It compared a specified semaglutide 1 mg regimen in adults with type-2 diabetes. Broader superiority claims need directly relevant evidence.
No. Approval concerns named pharmaceutical products and their specifications; it does not transfer through the ingredient name.
No. They are group estimates under defined study conditions, with variable responses and discontinuations.
This companion to the Tirzepatide research profile explains how to interpret experimental quantities. It provides no personal-use regimen.
Dose escalation, maintenance and follow-up are part of the trial design. A headline maintenance amount is not a complete treatment plan and should not be extracted for unsupervised use.
Different presentations contain different total quantities and concentrations. Current product-specific instructions and professional prescribing context take precedence over an old chart or a vendor’s vial-size label.
Find the tested material, formulation, route, study population, comparison group and observation period in the original paper. Exposure in a cell system or animal model does not supply a human starting amount, schedule or route.
Mass describes an amount of material; concentration describes that amount per final solution volume. One milligram equals 1,000 micrograms. Neither a vial label nor arithmetic establishes identity, stability, sterility or an appropriate use.
Read the units reference and the study summaries and their limitations. Use the original methods for the precise experimental conditions; do not transfer a reported amount between different materials or study models.
The main profile links the selected primary sources, distinguishes the study designs and explains what the findings cannot show. A trial registration is a research plan, not a published result.
Reviews
There are no reviews yet.